3 Top Growth Plays That Could Smash The FTSE 100: ARM Holdings plc, GlaxoSmithKline plc & Diageo plc

Though the FTSE 100 (INDEXFTSE:UKX) could go much higher, ARM Holdings plc (LON:ARM), GlaxoSmithKline plc (LON:GSK) & Diageo plc (LON:DGE) could beat it.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE100

With the S&P 500 hitting record highs, 2014 has been something of a disappointment for the FTSE 100. Indeed, the index is up just 1% since the turn of the year, but does seem to have huge potential over the medium term. That’s because it trades on a price to earnings (P/E) ratio of just 13.8 and has a yield of around 3.5% — both of which indicate that the index could push northwards.

However, here are three shares that despite the FTSE 100’s potential, could still outperform the UK’s main index.

ARM

Although shares in ARM (LSE: ARM) have fallen by 12% during the course of 2014, the intellectual property business could beat the FTSE 100 going forward. That’s because it offers investors a vast amount of growth potential, with the company’s earnings per share (EPS) expected to increase by an impressive 23% in 2015. Furthermore, with shares in ARM having fallen, they now represent much better value for money. Indeed, although ARM’s price to earnings (P/E) ratio remains high at 41.5, its price to earnings growth (PEG) ratio of just 1.5 means that it could outperform the FTSE 100 over the medium term.

GlaxoSmithKline

As with ARM, 2014 has been a tough year for GlaxoSmithKline (LSE: GSK). Its shares have dropped by 9% and the company continues to suffer from weak sentiment due to bribery allegations. However, GlaxoSmithKline also has a highly diversified and capable drugs pipeline that has the potential to deliver brisk earnings growth in future years. Certainly, all drug pipelines come with a large dollop of uncertainty, but GlaxoSmithKline appears to have a well-balanced pipeline that should benefit from a renewed focus by the company after the sale of its consumer brands. In the meantime, a yield of 5.6% should help to push investors’ total return above that of the FTSE 100.

Diageo

Diageo (LSE: DGE) is also down in 2014, with the alcoholic beverages company seeing its share price fall by 12% year-to-date. However, demand for premium alcoholic drinks should remain robust in the long run – even if the world economy does fall back into negative growth territory. Moreover, Diageo’s strong stable of brands should ensure that demand for its products remains buoyant in developed nations, while emerging markets such as China and India present a huge opportunity for the company to increase its sales and profitability. As a result, it could have a much brighter future and has the scope to beat the main index moving forward.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of GlaxoSmithKline. The Motley Fool UK has recommended shares in GlaxoSmithKline and ARM Holdings. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Down 20% this month, can this struggling FTSE 100 stock recover?

Shares in delivery company Ocado are down considerably this month, continuing a multi-year trend. Is there still hope for this…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 FTSE 100 high dividend shares to consider in May

I'm building a list of the best FTSE 100 income shares to buy this month. Here are two I'm expecting…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: Share Advisor’s latest lower-risk, higher-yield recommendation [PREMIUM PICKS]

Ice ideas will usually offer a steadier flow of income and is likely to be a slower-moving but more stable…

Read more »

Investing Articles

Here’s how I’d target passive income from FTSE 250 stocks right now

Dividend stocks aren't the only ones we can use to try to build up some long-term income. No, I like…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

If I put £10k in this FTSE 100 stock, it could pay me a £1,800 second income over the next 2 years

A FTSE 100 stock is carrying a mammoth 10% dividend yield and this writer reckons it could contribute towards an…

Read more »

Investing Articles

2 UK shares I’d sell in May… if I owned them

Stephen Wright would be willing to part with a couple of UK shares – but only because others look like…

Read more »

Investing Articles

2 FTSE 250 shares investors should consider for a £1,260 passive income in 2024

Investing a lump sum in these FTSE 250 shares could yield a four-figure dividend income this year. Are they too…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

This FTSE share has grown its decade annually for over 30 years. Can it continue?

Christopher Ruane looks at a FTSE 100 share that has raised its dividend annually for decades. He likes the business,…

Read more »